Close Menu

NEW YORK ─  Precision cancer diagnostics firm Epredia has been appointed a distributor of the Lunaphore Technologies LabSat Research platform, an automated tissue staining instrument for rapid immunohistochemistry and immunofluorescence, the firms said this week.

Next month, Epredia will begin distributing the product for research use in the US, United Kingdom, and Germany. Commercialization in Japan will begin next year, and Epredia will also distribute the platform there, the firms said.

Financial and other terms of the agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.